Vertex Pharmaceuticals has released late-stage trial results for VX-548, an investigational non-opioid pain medication showing safety, efficacy, and modest pain relief. While opioid medications remain common, the need for non-opioid options is evident due to risks associated with opioid use. Clinical development and reimbursement challenges in the non-opioid pain medication space have historically hindered progress. VX-548's potential approval raises questions about its coverage and efficacy compared to opioids, highlighting the complexities of managing pain effectively.